Literature DB >> 25682605

Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway.

Knut B Smeland1, Cecilie E Kiserud2, Grete F Lauritzsen3, Unn-Merete Fagerli4, Ragnhild S Falk5, Øystein Fluge6, Alexander Fosså3, Arne Kolstad3, Jon H Loge7, Martin Maisenhölder8, Stein Kvaløy9, Harald Holte3.   

Abstract

Entities:  

Keywords:  autologous stem cell transplantation; high-dose therapy; mortality; non-Hodgkin lymphoma; survival

Mesh：

Year:  2015        PMID： 25682605      PMCID： PMC4450639          DOI： 10.3324/haematol.2014.119214

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Authors:  Norbert Schmitz; Beate Pfistner; Michael Sextro; Markus Sieber; Angelo M Carella; Matthias Haenel; Friederike Boissevain; Reinhart Zschaber; Peter Müller; Hartmut Kirchner; Andreas Lohri; Susanne Decker; Bettina Koch; Dirk Hasenclever; Anthony H Goldstone; Volker Diehl
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

2.  Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness.

Authors:  Inger Kristin Larsen; Milada Småstuen; Tom Børge Johannesen; Frøydis Langmark; Donald Maxwell Parkin; Freddie Bray; Bjørn Møller
Journal:  Eur J Cancer       Date:  2008-12-16       Impact factor: 9.162

3.  Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma.

Authors:  Karyn A Goodman; Elyn Riedel; Victoria Serrano; Subhash Gulati; Craig H Moskowitz; Joachim Yahalom
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

4.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

Authors:  D C Linch; D Winfield; A H Goldstone; D Moir; B Hancock; A McMillan; R Chopra; D Milligan; G V Hudson
Journal:  Lancet       Date:  1993-04-24       Impact factor: 79.321

5.  Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study.

Authors:  Smita Bhatia; Leslie L Robison; Liton Francisco; Andrea Carter; Yan Liu; Marcia Grant; K Scott Baker; Henry Fung; James G Gurney; Philip B McGlave; Auayporn Nademanee; Norma K C Ramsay; Anthony Stein; Daniel J Weisdorf; Stephen J Forman
Journal:  Blood       Date:  2005-02-08       Impact factor: 22.113

6.  Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma.

Authors:  Ann Y Minn; Elyn Riedel; Jerry Halpern; Laura J Johnston; Sandra J Horning; Richard T Hoppe; Karyn A Goodman
Journal:  Br J Haematol       Date:  2012-09-12       Impact factor: 6.998

7.  Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma.

Authors:  Navneet S Majhail; Ruta Bajorunaite; Hillard M Lazarus; Zhiwei Wang; John P Klein; Mei-Jie Zhang; J Douglas Rizzo
Journal:  Br J Haematol       Date:  2009-07-01       Impact factor: 6.998

Review 8.  Late effects of Hodgkin's disease and its treatment.

Authors:  Andrea K Ng; Peter M Mauch
Journal:  Cancer J       Date:  2009 Mar-Apr       Impact factor: 3.360

9.  Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.

Authors:  Anna Czyz; Anna Lojko-Dankowska; Dominik Dytfeld; Adam Nowicki; Lidia Gil; Magdalena Matuszak; Maria Kozlowska-Skrzypczak; Maciej Kazmierczak; Ewa Bembnista; Mieczysław Komarnicki
Journal:  Med Oncol       Date:  2013-05-24       Impact factor: 3.064

10.  Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies.

Authors:  A M Vanderwalde; C-L Sun; L Laddaran; L Francisco; S Armenian; J Berano-Teh; F L Wong; L Popplewell; G Somlo; A S Stein; A Nademanee; A Krishnan; N Kogut; S J Forman; S Bhatia
Journal:  Leukemia       Date:  2012-11-07       Impact factor: 11.528
View more
  6 in total

1.  Diffusing capacity impairment is prevalent in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation.

Authors:  J S Stenehjem; K B Smeland; K Murbraech; H Holte; S Kvaløy; T Wethal; C E Kiserud; M B Lund
Journal:  Bone Marrow Transplant       Date:  2016-12-19       Impact factor: 5.483

2.  Survivorship after Autologous Hematopoietic Cell Transplantation for Lymphoma and Multiple Myeloma: Late Effects and Quality of Life.

Authors:  George E Georges; Merav Bar; Lynn Onstad; Jean C Yi; Mazyar Shadman; Mary E Flowers; Paul A Carpenter; Susan Stewart; Stephanie J Lee; Leona A Holmberg
Journal:  Biol Blood Marrow Transplant       Date:  2019-10-09       Impact factor: 5.742

3.  Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma.

Authors:  Brian D Friend; Ibrahim N Muhsen; Shreeya Patel; LaQuisa C Hill; Premal Lulla; Carlos A Ramos; S Ravi Pingali; Rammurti T Kamble; Tami D John; Baheyeldin Salem; Saleh Bhar; Erin E Doherty; John Craddock; Ghadir Sasa; Mengfen Wu; Tao Wang; Caridad Martinez; Robert A Krance; Helen E Heslop; George Carrum
Journal:  Bone Marrow Transplant       Date:  2022-02-01       Impact factor: 5.483

4.  Case Report: PD-1 Blockade Combined Autologous Hematopoietic Stem Cell Transplantation With Modified BEAM Regimen Containing High-Dose Cytarabine to Treat R/R Hodgkin's Lymphoma.

Authors:  Xiaoqi Wang; Kaniel Cassady; Zhongmin Zou; Xi Zhang; Yimei Feng
Journal:  Front Med (Lausanne)       Date:  2021-07-07

5.  Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation.

Authors:  Jo S Stenehjem; Knut B Smeland; Klaus Murbraech; Harald Holte; Stein Kvaløy; Lene Thorsen; Ingerid Arbo; Lee W Jones; Svend Aakhus; May Brit Lund; Cecilie E Kiserud
Journal:  Br J Cancer       Date:  2016-06-28       Impact factor: 7.640

6.  Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry.

Authors:  David A Jones; Paolo Candio; Rebecca Shakir; Georgios Ntentas; Johanna Ramroth; Alastair M Gray; David J Cutter
Journal:  Blood Adv       Date:  2022-02-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.